As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage…
MARKET OUTLOOKRelapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage…
Polycythemia Vera (PV) is a rare hematological malignancy estimated to affect approximately 50 thousand patients in the United States. Based on patient’s age and prior clinical history patients…
MARKET OUTLOOK Multiple Sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in the country. Two approved…
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL…
MARKET OUTLOOK Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has globally the highest number of RA patients, and the Chinese RA…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV …
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV …
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…